Pain relief methods for patients undergoing total knee arthroplasty : comparing adductor canal block and epidural analgesia.

A comparative study between continuous adductor canal block versus epidural analgesia for postoperative pain management in total knee arthroplasty patients - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/098759

Enrollment

Registered

2025-12-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

Intervention1: Adducor Canal Block: Patient will receive 0.125% levobupivacaine with fentanyl for post operative pain in patients of total knee Arthroplasty with continuous adductor canal block for 48

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade I and II patients

Exclusion criteria

Exclusion criteria: Subjects with history of allergy to local anaesthetics. Pregnant or lactating females. Infection or scarring at the site of Adductor Canal Block (ACB) /epidural block. Psychological disorders or linguistic difficulties that might interfere with pain assessment. History of bleeding disorders and coagulopathy

Design outcomes

Primary

Measure	Time frame
To evaluate the analgesic efficacy of 0.125% levobupivacaine with fentanyl for post operative pain in patients of total knee Arthroplasty with continuous adductor canal block. To evaluate the analgesic efficacy of 0.125% levobupivacaine with fentanyl for post operative pain in patients of total knee Arthroplasty with continuous epidural analgesia. To Compare the effect of continuous adductor canal blockade and epidural analgesia in post operative pain in total knee arthroplasty patients.Timepoint: Post Op pain monitoring of patient for every 2 hour for next 48 hour	—

Measure

Time frame

To evaluate the analgesic efficacy of 0.125% levobupivacaine with fentanyl for post operative pain in patients of total knee Arthroplasty with continuous adductor canal block. To evaluate the analgesic efficacy of 0.125% levobupivacaine with fentanyl for post operative pain in patients of total knee Arthroplasty with continuous epidural analgesia. To Compare the effect of continuous adductor canal blockade and epidural analgesia in post operative pain in total knee arthroplasty patients.Timepoint: Post Op pain monitoring of patient for every 2 hour for next 48 hour

—

Secondary

Measure	Time frame
To evaluate the analgesic efficacy of 0.125% levobupivacaine with fentanyl for post operative pain in patients of total knee Arthroplasty with continuous adductor canal block. To evaluate the analgesic efficacy of 0.125% levobupivacaine with fentanyl for post operative pain in patients of total knee Arthroplasty with continuous epidural analgesia. To Compare the effect of continuous adductor canal blockade and epidural analgesia in post operative pain in total knee arthroplasty patients.Timepoint: To do intra or hemodynamic monitoring and post operative monitoring for every patient for 48 hours	—

Measure

Time frame

To evaluate the analgesic efficacy of 0.125% levobupivacaine with fentanyl for post operative pain in patients of total knee Arthroplasty with continuous adductor canal block. To evaluate the analgesic efficacy of 0.125% levobupivacaine with fentanyl for post operative pain in patients of total knee Arthroplasty with continuous epidural analgesia. To Compare the effect of continuous adductor canal blockade and epidural analgesia in post operative pain in total knee arthroplasty patients.Timepoint: To do intra or hemodynamic monitoring and post operative monitoring for every patient for 48 hours

—

Countries

India

Contacts

Public ContactDr Mukesh Kumar

Guru Gobind Singh Medical College Hospital, Faridkot

mukeshtala@gmail.com09464887097

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026